source
- ARPA-H earmarks $160 million for custom gene-editing therapies, sparking debate on adequacyARPA-H announced a $160 million investment to support development of bespoke gene‑editing treatments. This follows a recent case where an infant was rescued from a lethal disease using a personaliz…
- AstraZeneca and Ionis report failure of eplontersen in ATTR-CM trialAstraZeneca and Ionis said their nucleic‑acid drug eplontersen did not meet the primary goal in a large study of patients with transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM). Over a 140‑we…